Maxx Chatsko

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

120 fish bowl jump

Should Amyris Split Into 2 Companies?

Unlocking the true value of the company's consumer portfolio might require a big, bold decision.


businessman stock down

Here's Why Teva Pharmaceutical Fell as Much as 15.4% Today

The United States is suing the drugmaker. Again.


563 shocked phone

Here's Why Unity Biotechnology Is Getting Crushed Today

The development-stage biopharma announced disappointing results from a clinical trial.


026 question mark on wooden table

Personalis Turns to Liquid Biopsies for Growth. Will It Work?

The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.


564 model of DNA

Twist Bioscience Is Rapidly Growing Its Customer Base. Can It Turn a Profit?

The DNA synthesis leader is rapidly expanding its product offerings, but losses continue to grow. Maybe it doesn't matter after all.

600 scientist microscope

Here's Why Omeros Fell Over 13% Today

The biopharma announced the pricing of a public offering of common stock and debt offering.


multiple lines down

Here's Why Personalis Fell as Much as 13.8% Today

The genomics company announced a public offering of common stock.


152 building blocks stairs

Coherus BioSciences Keeps Proving Wall Street Wrong

The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?


chalkboard stock down pink

Mesoblast Plunges as FDA Questions Cell-Therapy Manufacturing

The Australian stem-cell company will face some pointed questions from regulators about how it manufactures stem cells.


120 fish bowl jump

Codexis Dodges Coronavirus Slowdown in Q2

R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.

143 oil refinery

Albemarle Reports 41% Decline in Q2 Net Income

Investors will have to expect much of the same in the second half of the year.


stock down angry fist

Amyris Reports Its Largest First-Half Operating Loss Since 2012

A growing balance of deferred cost of product revenue suggests business fundamentals might be significantly worse than reported.


arrow up shelves

Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today

A rumored merger has investors excited, although details are scarce.


410 binoculars kid

What to Watch When Twist Bioscience Reports Fiscal Q3 Results

Can the company possibly live up to its lofty market valuation?


076 arrow dude getty

Renewable Energy Group Posts Surprise Q2 Profit

The biomass-based diesel manufacturer smashed through its own lowly expectations thanks to a boost from state and federal incentives.

327 pipeline

Does the Hydrogen Economy Have a Pipeline Problem?

Manufacturing hydrogen from renewable energy sounds great, but there are significant limitations to transporting hydrogen fuels.


022 roller coaster

NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound

The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.


410 binoculars kid

What to Watch When Albemarle Reports Q2 Earnings

The specialty chemicals manufacturer is expected to struggle in 2020, but it has undertaken significant efforts to preserve long-term business fundamentals.


464 diesel truck

What to Watch When Renewable Energy Group Reports

The renewable fuels manufacturer is contending with a historic slowdown in demand for transportation fuels. Are diesel fuels more insulated from uncertainty?


058 by the numbers

Repligen Reports Record Quarter, Increases 2020 Guidance

The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.